CTOs on the Move

Carrot Fertility

www.get-carrot.com

 
Carrot is a complete global fertility solution for today`s modern employers and payers, providing flexible financial coverage and expert care navigation across the U.S. and 50+ countries. Get a quick demo and briefing about how modern companies are using Carrot to drive down healthcare costs, attract and retain top talent, and build cultures of inclusion.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Jobs

VP, Chief Information Security Officer

Carrot Fertility Remote

Funding

Carrot Fertility raised $24M on 08/18/2020

Similar Companies

Hoya Vision

Driven by a passion for partnership as well as innovation, HOYA has been a partner to Eye Care Professionals for over 75 years, enabling them to give people the greatest gift, the gift of vision. We provide Eye Care Professionals with the lenses, consultation solutions and other services that help them to develop their practice while changing the way people see the world. We see them as visionaries, and everything we do is for them. Founded in Japan in 1941, today, HOYA has a presence in over 80 countries across the globe.

Lawall Orthotics and Prosthetics

Lawall Orthotics and Prosthetics is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ardea Biosciences

Ardea Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autism Family Center

Autism Family Center fulfills a critical need for a coordinated, multidisciplinary approach to treating Autistic Disorder by providing a full range of services including Applied Behavior Analysis (ABA). Because we view families as an integrated system and believe that the health of every member is vital for each member to thrive, Autism Family Center provides support services for the entire family. Our process is designed to ensure maximum learning, unity and happiness.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.